Advanced Cancer

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

By

Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

By

Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).

Nurses Must Be Experienced, Feel Competent When Providing End-of-Life Care

Nurses Must Be Experienced, Feel Competent When Providing End-of-Life Care

By

An analysis of select responses to a survey conducted by researchers from the College of Nursing at South Dakota State University identified oncology nurses' comfort level in handling end-of-life care and patient education.

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

By

Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

By

Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.

Outcomes Best With Discharge to Home vs PAC or Hospice in Advanced Cancer

Outcomes Best With Discharge to Home vs PAC or Hospice in Advanced Cancer

By

In a prospective study, researchers assessed survival and quality of life measures for patients with advanced cancer in relation to where they are discharged from hospital: postacute care (PAC), hospice, or home without hospice.

Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer

Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer

By

Previous studies have shown that patients with advanced cancer may experience some financial relief integrating palliative care with standard oncologic care, but these results were coincidental findings and have not yet been fully explored.

WWW: Navigating Complex Conversations Regarding Patients With Advanced Disease

WWW: Navigating Complex Conversations Regarding Patients With Advanced Disease

By

WWW is not for the world-wide web, but it is an easy way to remember the 3 w's of communication with patients with advanced disease: wish, worry, wonder.

Hospitalizations in Advanced Cancer: What Makes Patients Stay or Come Back

Hospitalizations in Advanced Cancer: What Makes Patients Stay or Come Back

By

Investigators conducted a study involving more than 1000 patients with advanced cancer to assess the factors that contribute to prolonged hospital stays and increased risk for readmissions.

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

By

Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.

Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose

Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose

By

A smaller dose of cabazitaxel (C20) is noninferior to a larger dose (C25) in the post-docetaxel treatment of mCRPC.

Combination Better At Easing Agitated Delirium in Advanced Cancer Patients

Combination Better At Easing Agitated Delirium in Advanced Cancer Patients

By

Lorazepam plus haloperidol is more effective than haloperidol alone at reducing agitation, study finds.

Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases

Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases

By

Palliative radiotherapy for bone metastases is safe, effective — but controversy persists for single-fraction treatment.

Walking Improves Quality of Life in Patients with Advanced Cancer

Walking Improves Quality of Life in Patients with Advanced Cancer

By

Simply walking for 30 minutes 3 times a week has significant impact on symptom severity and ability to cope, as well as quality of life, for patients with advanced cancer.

No Association Between Vasectomy and Prostate Cancer Risk

No Association Between Vasectomy and Prostate Cancer Risk

By

There is no association between vasectomy and the risk of overall, high-grade, or advanced-stage prostate cancer or prostate cancer-related mortality.

Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure

Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure

By

Treatment expectations of individuals with metastatic prostate cancer and their health care providers often do not match.

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

By

Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

By

A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.

Half of Patients With Advanced Cancer Believe They Will Be Cured

Half of Patients With Advanced Cancer Believe They Will Be Cured

By

Nearly half of patients with advanced cancer around the world believe they will be cured, with the perception of curability significantly differing by education, performance status, and country of origin.

Methylnaltrexone Linked to Improved Survival in Advanced Cancer

Methylnaltrexone Linked to Improved Survival in Advanced Cancer

By

Treatment with methylnaltrexone was associated with improved overall survival in patients with advanced cancer.

Use, Outcomes of Urine Drug Tests Among Patients With Advanced Cancer

Use, Outcomes of Urine Drug Tests Among Patients With Advanced Cancer

By

Despite the infrequency of urine drug test ordering, greater than half of all urine drug tests results were abnormal among outpatients with advanced cancer.

Increasing Weight Associated With Disease Progression in Multiple Myeloma

Increasing Weight Associated With Disease Progression in Multiple Myeloma

By

Increasing body mass index (BMI) allows growth and progression of disease in patients with multiple myeloma, a recently published study has shown.

Advanced Cancer Patients Often Unaware That They Are More Optimistic About Their Prognosis Than Their Oncologists

Advanced Cancer Patients Often Unaware That They Are More Optimistic About Their Prognosis Than Their Oncologists

By

Most patients with advanced cancer report far more optimistic expectations for survival prognosis than their oncologists because patients misunderstand their oncologists' clinical judgment.

Trastuzumab Biosimilar Comparable the Monoclonal Antibody for Advanced HER2+ Breast Cancer

By

MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.

Web Application Improves Follow-up in Patients With Advanced Lung Cancer

Web Application Improves Follow-up in Patients With Advanced Lung Cancer

By

A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.

Poor Sleep Quality Negatively Impacts Some Adverse Effects in Patients With Advanced Cancer

Poor Sleep Quality Negatively Impacts Some Adverse Effects in Patients With Advanced Cancer

By

Patients participating in early-phase clinical trials should be assessed for sleep quality, as poor sleep quality is associated with greater fatigue, symptom burden, and mood disturbance.

Improving Tools for Managing Pain and Monitoring Sedation Among Patients With Cancer

Improving Tools for Managing Pain and Monitoring Sedation Among Patients With Cancer

By

Managing pain with opioids and keeping a close eye on adverse effects is an important part of cancer care. But there is room for improvement in pain management tools, and nurses play a key role in their evolution.

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

By

In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

By

Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs